CPNP will once again feature the popular point-counterpoint debate session at the 2010 Annual Meeting, this year on the topic of Antipsychotic Efficacy versus Adverse Effects. Drs. Peter Buckley (Professor and Chairman, Department of Psychiatry and Behavioral Health at the Medical College of Georgia) and Henry Nasrallah (Professor of Psychiatry, Neurology and Neuroscience and Director of the Schizophrenia Research Program at the University of Cincinnati College of Medicine) will provide a thorough discussion of the relative efficacy and tolerability profiles of the typical antipsychotic versus the atypical antipsychotics, in the context of individualizing treatments for patients with schizophrenia. The format of the session will be designed to provide a review of the available literature followed by a debate format between these two well-known clinical researchers. Read on to gain a small preview into this topic and the session to be featured at the CPNP Annual Meeting. Read more about this session.
Clozapine is a highly effective atypical antipsychotic. It is hepatically transformed to N-desmethylclozapine (NDMC, norclozapine, primary metabolite) and clozapine-N-oxide (CNO). Omeprazole is a commonly utilized proton pump inhibitor that is an inducer and inhibitor of the hepatic CYP450 1A2 isoform, as well as an inhibitor of CYP3A4, 2C19, 2C9 and 2D6. There are several case reports of omeprazole interacting with clozapine, however the observed change in clozapine concentration varies from report to report and there is much heterogeneity between baseline characteristics of the patients in the reported cases.
Low Absolute Neutrophil Count (ANC), can lead to Agranulocytosis. Clozapine is well known to cause low ANC. Recent research on other psychiatric medications has identified drug induced neutropenia.